Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 53.00 | |
2 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 126.00 | |
10 mg | In stock | $ 218.00 | |
25 mg | In stock | $ 463.00 | |
50 mg | In stock | $ 682.00 | |
100 mg | In stock | $ 969.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 133.00 |
Description | CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity. |
Targets&IC50 | CLK1:0.67 nM, CLK2:15 nM, CLK3:110 nM |
In vitro | CLK-IN-T3 (0.5, 1.0 μM) decreases the phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. CLK-IN-T3 (0.1, 0.5, 1.0, 5.0, 10.0 µM) results in mild cell cycle arrest at the G2/M boundary with a long-duration of 24 h. CLK-IN-T3 inhibits DYRK1A and DYRK1B with IC50s of 260 and 230 nM[1]. |
Molecular Weight | 482.58 |
Formula | C28H30N6O2 |
CAS No. | 2109805-56-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.5 mg/mL (9.32 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CLK-IN-T3 2109805-56-1 Cell Cycle/Checkpoint Tyrosine Kinase/Adaptors CDK DYRK CDC-like Dual specificity tyrosine phosphorylation regulated kinase inhibit Dual specificity tyrosine regulated kinase stable anti-cancer CLK kinase CLK-IN-T-3 CLKINT3 DYRK1A Inhibitor activity CLK IN T3 DYRK1B Cyclin dependent kinase inhibitor